Auris Medical (NDAQ:EARS) Price Target & New Coverage by Roth Capital
Roth Capital analyst began coverage on Auris Medical (NDAQ:EARS) with a $4.50 target price per share and “Buy” rating. The target price per share would indicate a potential upside of 500.00 % from firm’s current stock price.
The new coverage is well-received by equity trades, as NDAQ:EARS is now trading 3.81% higher at $0.75 as of 2:00 PM New York time. Auris Medical shares have [From2] 0% in the last 200 days, while the S&P500 Index has added 14.38% in the same time period.
Out of 4 brokers covering Auris Medical, 4 rate it a Buy, 0 indicate a Hold while 0 suggest a Sell. The highest target is $12 and the lowest is $11 according to Thomson/First Call. The 12-month mean target is $11.75, which means upside potential of 1466.67% over the current price.
Auris Medical (NDAQ:EARS) Profile
Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL).
Auris Medical (NDAQ:EARS) traded up 3.81% on 14 April, hitting $0.75. A total of 439,863 shares of the company’s stock traded hands. This is down from average of 686,926 shares. Auris Medical has a 52 week low of $0.62 and a 52 week high of $5.45. The company has a market cap of $26.65M and a P/E ratio of 0.
Get the latest Auris Medical (NDAQ:EARS) Stock Ratings at Octafinance. Completely free access to our Analyst Ratings Database for 6000+ stocks.
The post Why Roth Capital Initiated Coverage On Auris Medical (NDAQ:EARS) Stock With “Buy” Rating appeared first on Octafinance.